# MetaSight Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/metasight-diagnostics

- Industry: Biotechnology
- Headquarters: Rehovot, Israel
- Website: www.metasightdx.com/
- Total disclosed funding: $8M
- Latest round: Series A (Nov 13, 2024)
- Investors on record: 4

## About

Based in Israel, MetaSight Diagnostics Ltd develops advanced diagnostic solutions through innovative blood testing methodologies, focusing on early disease detection and monitoring.MetaSight Diagnostics Ltd, founded in 2021 and headquartered in Rehovot, Israel, specializes in innovative diagnostics. The company has engaged in one significant funding round, raising USD 8.000 mn in Series A funding on November 13, 2024, with investments from aMoon, Saban Ventures, ARC Ventures, and Alumni Ventures Group. The founder, Tomer Shlomi, has a background that contributes to the company's vision, although further details on his previous ventures are not specified.MetaSight specializes in developing innovative disease diagnostics and monitoring solutions through advanced blood testing methodologies. Their core offerings are based on proprietary high-throughput mass-spectrometry multi-OMICs technology that analyzes biological samples at a molecular level. This technology includes population-scale serum sample collection and continuous access to electronic health records, addressing significant healthcare challenges in early disease detection and monitoring. MetaSight serves healthcare providers, research institutions, and clinical laboratories across North America, Europe, and parts of Asia.MetaSight's revenue model is primarily based on partnerships and clinical studies leveraging its advanced diagnostic technologies. The company collaborates with healthcare institutions and laboratories, providing access to its diagnostic tools and supporting services. Clients typically enter agreements for large-scale screening initiatives, such as the Israel Multi-OMICS Screening Trial, which has engaged over half a million participants. The pricing structure is based on the specific diagnostic tests and services utilized, ensuring a steady revenue stream through ongoing service agreements.Following the recent Series A funding of USD 8.000 mn raised on November 13, 2024, MetaSight Diagnostics Ltd plans to expand its diagnostic product portfolio and advance its current programs into FDA trials. The company aims to broaden its market reach, targeting new geographical regions for expansion, although specific locations have not been disclosed.

## Funding rounds

- Series A, Nov 13, 2024, $8M — Alumni Ventures Group, aMoon, Saban Ventures, Arc Ventures

## Investors

- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- aMoon (https://capitalatlas.ai/funds/amoon) — Series A
- Saban Ventures (https://capitalatlas.ai/funds/saban-ventures) — Series A
- Arc Ventures — Series A